Upregulation of osteoclast α2β1 integrin compensates for lack of αvβ3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia

British Journal of Haematology

Volumn 122, Issue 6, 2003, Pages 950-957

  Horton, Michael A ^a,c   Massey, Helen M ^a,d   Rosenberg, Nurit ^b   Nicholls, Brian ^a   Seligsohn, Uri ^b   Flanagan, Adrienne M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b TEL AVIV UNIVERSITY   (Israel)

^c Department of Medicine   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

v 3 integrin; Bone resorption; Glanzmann thrombasthenia; Osteoclast; Platelet IIb 3 fibrinogen receptor; Vitronectin receptor

Indexed keywords

ALPHA2 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; FIBRINOGEN RECEPTOR; INTEGRIN; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VERY LATE ACTIVATION ANTIGEN 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING TENDENCY; CELL ACTIVITY; CELL LINE; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ETHNIC DIFFERENCE; FEMALE; GLANZMANN DISEASE; HUMAN; HUMAN CELL; MALE; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCANNING ELECTRON MICROSCOPY; BLOOD; BONE; CELL CULTURE; CONFOCAL MICROSCOPY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; ULTRASTRUCTURE; UPREGULATION;

ADOLESCENT; ADULT; AGED; BONE AND BONES; BONE RESORPTION; CELLS, CULTURED; CHILD; FEMALE; HUMANS; INTEGRIN ALPHA2BETA1; INTEGRIN ALPHAVBETA3; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; OSTEOCLASTS; THROMBASTHENIA; UP-REGULATION;

EID: 0141651720     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04530.x     Document Type: Article

References (28)

1. Bader, B.L., Rayburn, H., Crowley, D. & Hynes, R.O. (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell, 95, 507-519.
2. Beckstead, J.H., Stenberg, P.E., McEver, R.P., Shuman, M.A. & Bainton, D.F. (1986) Immunohistochemical localization of membrane and alpha-granule proteins in human megakaryocytes: application to plastic embedded bone marrow biopsy specimens. Blood. 67, 285-293.
3. Coller, B.S., Seligsohn, U., Zivelin, A., Zwang, E., Lusky, A. & Modan, M. (1986) Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. British Journal of Haematology, 62, 723-735.
4. Coller, B.S., Cheresh, D.A., Asch, E. & Seligsohn, U. (1991) Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 77, 75-83.
5. Coller, B.S., Seligsohn, U., Peretz, H. & Newman, P.J. (1994) Glanzmann thrombasthenia: new insights from an historical perspective. Seminars in Hematology, 31, 301-311.
6. Drake, F.H., Dodds, R.A., James, I.E., Connor, J.R., Debouck, C., Richardson, S., Lee-Rykaczewski, E., Coleman, L., Rieman, D., Barthlow, R., Hastings, G. & Gowen, M. (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. Journal of Biological Chemistry, 271, 12511-12516.
7. Fang, X., Novack, D.V., Faccio, R., Ory, D.S., Aya, K., Boyer, M.I., McHugh, K.P., Ross, F.P. & Teitelbaum, S.L. (2001) A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. Journal of Clinical Investigations, 107, 1137-1144.
8. Hartman, G.D. & Duggan, M.E. (2000) αvβ3 integrin antagonists as inhibitors of bone resorption. Expert Opinions on Investigational Drugs, 9, 1281-1291.
9. Helfrich, M.H. & Horton, M.A. (1999) Integrins and adhesion molecules. In: Dynamics of Bone and Cartilage Metabolism (ed. by M.J., Seibel, S.P. Robins & J.P. Bilezikian), pp. 111-125. Academic Press, San Diego, USA.
10. Helfrich, M.H., Nesbitt, S.A., Lakkakorpi, P.T., Barnes, M.J., Bodary, S.C., Shankar, G., Mason, W.T., Mendrick, D.L., Vaananen, H.K. & Horton, M.A. (1996) Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption. Bone, 19, 317-328.
11. Horton, M.A. (2001) Integrin antagonists as inhibitors of bone resorption: implications for treatment. Proceedings of the Nutritional Society, 60, 275-281.
12. Horton, M.A., Lewis, D., McNulty, K., Pringle, J.A.S. & Chambers, T.J. (1985) Monoclonal antibodies to osteoclastomas (giant cell bone tumours): definition of osteoclast-specific cellular antigens. Cancer Research, 45, 5663-5669.
13. Horton, M.A., Nesbitt, S.A., Bennett, J.H. & Stenbeck, G. (2002) Integrins and Other Cell Surface Attachment Molecules of Bone Cells. In: Principles of Bone Biology, 2nd edn (ed. by J.P. Bilezikian, L.G. Raisz & G.A. Rodan), pp. 265-286. Academic Press, San Diego, USA.
14. Lacey, D.L., Timms, E., Tan, H.-L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Elliot, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.-X., Kaufman, S., Sarosi, I., Shaloub, V., Senaldi, G., Guo, J., Delaney, J. & Boyle, W.J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, 165-176.
15. Lader, C.S., Scopes, J., Horton, M.A. & Flanagan, A.M. (2001) Generation of human osteoclasts in stromal cell-free and stromal cell-rich cultures: differences in osteoclast CD11c/CD18 integrin expression. British Journal of Haematology, 112, 430-437.
16. McHugh, K.P., Hodivala-Dilke, K., Zheng, M.-H., Namba, N., Lam, J., Novack, D., Feng, X., Ross, F.P., Hynes, R.O. & Teitelbaum, S.L. (2000) Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. Journal of Clinical Investigation, 105, 433-440.
17. McSheehy, P.M.J. & Chambers. T.J. (1986) Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology, 118, 824-828.
18. Massey, H.M. & Flanagan, A.M. (1999) Human osteoclasts derive from CD14-positive monocytes. British Journal of Haematology, 106, 167-170.
19. Massey, H.M., Scopes, J., Horton, M.A. & Flanagan, A.M. (2001) Transforming growth factor-β1 (TGF-β) stimulates the osteoclastforming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment. Bone, 28, 577-582.
20. Miller, W.H., Keenan, R., Willette, R.N. & Lark, M.W. (2000) Identification and in vivo efficacy of small molecule antagonists of integrin αvβ3 (the 'vitronectin receptor'). Drug Discovery Today, 5, 397-408.
21. Nesbitt, S.A. & Horton, M.A. (1997) Trafficking of matrix collagens through bone-resorbing osteoclasts. Science, 276, 266-269.
22. Nesbitt, S., Nesbit, A., Helfrich, M. & Horton, M. (1993) Biochemical characterisation of human osteoclast integrins. Osteoclasts express αvβ3, α2β1 and αvβ1 integrins. Journal of Biological Chemistry, 268, 16737-16745.
23. Newman, P.J., Seligsohn, U., Lyman, S. & Coller, B.S. (1991) The molecular genetic basis of Glanzmann's thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proceedings of the National Academy of Sciences of the USA, 88, 3160-3164.
24. Rosenberg, N., Dardik, R., Rosenthal, E., Zivelin, A. & Seligsohn, U. (1998) Mutations in the αIIB and β3 genes that cause Glanzmann thrombasthenia can be distinguished by a simple procedure using transformed B-lymphocytes. Thrombosis and Haemostasis, 79, 244-248.
25. Sarma, U. & Flanagan, A.M. (1996) Macrophage-colony stimulating factor (M-CSF) induces substantial osteoclast formation in human bone-marrow cultures. Blood, 88, 2531-2540.
26. Scopes, J., Massey, H.M., Ebrahim, H., Horton, M.A. & Flanagan, A.M. (2001) Interleukin-4: bidirectional effects on human osteoclast formation. Bone, 29, 203-208.
27. Seligsohn, U. & Rososhansky, S. (1984) A Glanzmann's thrombasthenia cluster among Iraqi Jews in Israel. Thrombosis and Haemostasis, 52, 230-231.
28. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. & Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factory and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the USA, 95, 3597-3602.